MacroGenics マネジメント

マネジメント基準チェック /34

MacroGenicsの CEO はScott Koenigで、 Sep2001年に任命され、の在任期間は 23.17年です。の年間総報酬は$ 3.71Mで、 19%給与と81%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の2.07%を直接所有しており、その価値は$ 4.21M 。経営陣と取締役会の平均在任期間はそれぞれ7.8年と7.4年です。

主要情報

Scott Koenig

最高経営責任者

US$3.7m

報酬総額

CEO給与比率	19.0%
CEO在任期間	23.2yrs
CEOの所有権	2.1%
経営陣の平均在職期間	7.8yrs
取締役会の平均在任期間	7.4yrs

経営陣の近況

Recent updates

Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Aug 01

MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Jul 30

We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Jul 12

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

May 13

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

May 13

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

Apr 05

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 28

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Oct 25

MacroGenics: No Near-Term Catalysts

Oct 11

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Sep 02

MacroGenics Q2 2022 Earnings Preview

Aug 05

Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

Jul 25

MacroGenics halts mid-stage head and neck cancer study after fatalities

Jul 11

The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

May 09

We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Apr 12

CEO報酬分析

MacroGenics の収益と比較して、Scott Koenig の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$136m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$4m	US$705k	-US$9m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$7m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$5m	US$673k	-US$120m
Sep 30 2022	n/a	n/a	-US$191m
Jun 30 2022	n/a	n/a	-US$219m
Mar 31 2022	n/a	n/a	-US$217m
Dec 31 2021	US$5m	US$651k	-US$202m
Sep 30 2021	n/a	n/a	-US$146m
Jun 30 2021	n/a	n/a	-US$129m
Mar 31 2021	n/a	n/a	-US$136m
Dec 31 2020	US$3m	US$656k	-US$130m
Sep 30 2020	n/a	n/a	-US$158m
Jun 30 2020	n/a	n/a	-US$167m
Mar 31 2020	n/a	n/a	-US$152m
Dec 31 2019	US$5m	US$590k	-US$152m
Sep 30 2019	n/a	n/a	-US$166m
Jun 30 2019	n/a	n/a	-US$155m
Mar 31 2019	n/a	n/a	-US$167m
Dec 31 2018	US$5m	US$599k	-US$171m
Sep 30 2018	n/a	n/a	-US$21m
Jun 30 2018	n/a	n/a	-US$34m
Mar 31 2018	n/a	n/a	-US$32m
Dec 31 2017	US$3m	US$554k	-US$20m

報酬と市場: Scottの総報酬 ($USD 3.71M ) は、 US市場 ($USD 1.48M ) の同規模の企業の平均を上回っています。

報酬と収益: Scottの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Scott Koenig (72 yo)

23.2yrs

在職期間

US$3,705,825

報酬

Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Scott Koenig	President	23.2yrs	US$3.71m	2.07% $ 4.2m
James Karrels	Senior VP	16.5yrs	US$1.58m	0.27% $ 555.5k
Stephen Eck	Senior VP of Clinical Development & Chief Medical Officer	4.3yrs	US$1.75m	0.016% $ 31.7k
Eric Risser	Chief Operating Officer	2.8yrs	US$1.92m	0.062% $ 126.0k
Thomas Spitznagel	Senior Vice President of Technical Operations	2yrs	US$1.88m	0.013% $ 26.9k
Ezio Bonvini	Senior VP of Research & Chief Scientific Officer	8.2yrs	US$2.29m	0.16% $ 326.9k
Jeffrey Peters	Senior VP	7.4yrs	データなし	データなし
Lynn Cilinski	VP, Controller & Treasurer	21.1yrs	データなし	0.0099% $ 20.1k

7.8yrs

平均在職期間

61.5yo

平均年齢

経験豊富な経営陣: MGNXの経営陣は経験豊富で経験豊富です（平均在職期間は7.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Scott Koenig	President	23.2yrs	US$3.71m	2.07% $ 4.2m
David Stump	Independent Director	11.2yrs	US$160.75k	0.0072% $ 14.6k
Federica O'Brien	Independent Director	3.8yrs	US$152.00k	0.0072% $ 14.6k
Edward Hurwitz	Independent Director	20.1yrs	US$147.63k	0.060% $ 121.7k
Margaret Liu	Independent Director	1.8yrs	US$318.32k	0.0072% $ 14.6k
William Heiden	Independent Chairman of the Board	2.5yrs	US$180.13k	0.0072% $ 14.6k
Meenu Chhabra Karson	Independent Director	1.8yrs	US$335.41k	0.0072% $ 14.6k
Scott Jackson	Independent Director	7.8yrs	US$167.63k	0.0072% $ 14.6k
Jay Siegel	Independent Director	7yrs	US$167.21k	0.0072% $ 14.6k
Karen Jean Ferrante	Independent Director	7.8yrs	US$135.75k	0.0072% $ 14.6k

7.4yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: MGNXの取締役会は経験豊富であると考えられます ( 7.4年の平均在任期間)。

MacroGenics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year

President exercised options and sold US$250k worth of stock

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Recent updates

Consensus revenue estimates increase by 17%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year

MacroGenics, Inc. Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

Price target decreased by 9.4% to US$7.25

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Macrogenics Provides Vobramitamab Duocarmazine Update

Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Price target decreased by 25% to US$8.11

MacroGenics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Block & Leviton Files Lawsuit Against MacroGenics, Inc

We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

New major risk - Financial position

Consensus EPS estimates fall by 18%

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

New minor risk - Share price stability

Consensus revenue estimates fall by 21%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Price target increased by 9.9% to US$16.00

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

President exercised options and sold US$250k worth of stock

MacroGenics: Trying To Build A Better Everything

Price target increased by 8.1% to US$14.78

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Price target increased by 12% to US$14.33

Insider notifies of intention to sell stock

There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Insider notifies of intention to sell stock

Consensus EPS estimates increase by 17%, revenue downgraded

Investor sentiment improves as stock rises 18%

Consensus revenue estimates decrease by 25%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Investor sentiment deteriorates as stock falls 15%

Insider recently bought US$74k worth of stock

Investor sentiment deteriorates as stock falls 16%

Consensus revenue estimates increase by 17%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MacroGenics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus EPS estimates fall by 13%

Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

Consensus revenue estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

MacroGenics, Inc. to Report Q1, 2023 Results on May 09, 2023

Price target increased by 11% to US$11.75

Consensus revenue estimates increase by 42%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Consensus EPS estimates fall by 10%

Macrogenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients

Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Price target decreased to US$10.40

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

Price target increased to US$12.33

Consensus revenue estimates increase by 11%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MacroGenics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

マネジメント基準チェック /34